Handelsavisen
prelaunch
Companies Healthcare PHAR.CM
PH
PHAR.CM Pharmaceuticals

Colombo City Holdings PLC

$158,25
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
391,1 %
ROE
9,6 %
Net margin
517,2 %
Debt / equity
0,11
Beta
52w range
Volume
122
Day range
$13,48–$13,77
Prev close
$13,41
Open
$13,61
Next earnings
Ex-dividend
TR 1Y
About

Colombo City Holdings PLC operates in the real estate rental, development, and operations sector, generating revenue primarily through property development and management activities.

Business. Colombo City Holdings PLC (PHAR.CM) operates in the real estate rental, development, and operations industry. The company generates revenue primarily through rental income. Specific details regarding its operating segments, headquarters location, and primary stock exchange listing are not provided in the available data.

Classification99 %
SectorHealth Care
Industry groupPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY6 analysts
6 buy0 hold0 sell
Avg 12m price target2,21

Analyst recommendations

6 analysts · consensus Buy
Buy6
Hold0
Sell0
12-month price target
2,21
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
6 analysts · indicative
Ownership
Morgan Stanley Smith Barney LLC
largest disclosed fund holder
Profitability
9,6 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning PHAR.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to PHAR.CM. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Colombo City Holdings PLC (PHAR.CM) operates in the real estate rental, development, and operations industry. The company generates revenue primarily through rental income. Specific details regarding its operating segments, headquarters location, and primary stock exchange listing are not provided in the available data.

    Classification99 %
    SectorHealth Care
    Industry groupPharmaceuticals
    AI synthesis
    GENERATED

    Colombo City Holdings PLC maintains a strong liquidity position, with a current ratio of 4.75, indicating the company can cover its short-term liabilities more than four times over. However, the company reported negative operating cash flow of -53,777,280 LKR, which contrasts with its positive free cash flow of 258,018,330 LKR, suggesting capital expenditures are being offset by other cash inflows. The company's debt-to-equity ratio of 0.11 indicates a conservative capital structure, with total liabilities of 675,023,910 LKR compared to total equity of 2,699,756,220 LKR.

    The company's profitability is robust, with a return on equity (ROE) of 9.58% and a return on assets (ROA) of 7.66%, both exceeding the typical thresholds for the real estate development and operations industry. The net income of 258,630,480 LKR and operating income of 195,573,340 LKR reflect strong operational performance, supported by a gross profit of 47,035,930 LKR.

    The company's revenue is not segmented by geographic region or business line in the available data, but the primary source of income is derived from property development and management activities. There is no indication of significant geographic diversification or segment-specific performance metrics in the provided financials.

    The company's growth trajectory is not explicitly outlined in the available data, but the positive free cash flow and strong ROE suggest a stable and potentially growing business. The capital expenditure of -1,224,320 LKR indicates minimal investment in new projects, which may suggest a focus on maintaining existing assets rather than aggressive expansion.

    The risk assessment indicates a medium liquidity risk, primarily due to the negative net cash position after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential reported in the basic shares outstanding. The company's conservative debt structure and strong equity position mitigate credit risk, but the negative operating cash flow introduces some uncertainty regarding short-term liquidity.

    There are no recent events or filings explicitly mentioned in the provided data. The financial snapshot is based on the latest available market data data, and no additional transcripts or filings are referenced in the input.

    Key takeaways
    • Colombo City Holdings PLC has a strong equity position and conservative debt structure, with a debt-to-equity ratio of 0.11.
    • The company's return on equity (9.58%) and return on assets (7.66%) are strong indicators of profitability and efficient asset use.
    • Despite a negative operating cash flow, the company maintains a positive free cash flow, suggesting effective cash management.
    • The company's liquidity risk is moderate, with a current ratio of 4.75, but the negative net cash position after debt raises some concerns.
    • The company's growth appears to be stable, with minimal capital expenditures and a focus on maintaining existing assets.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $158,25
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $2.70B
    Net cash
    -$300.7M
    Current ratio
    4.8
    Debt / equity
    0.1
    ROA
    7.7%
    ROE
    9.6%
    Cash conversion
    -21.0%
    CapEx / revenue
    -2.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryPharmaceuticals695,2B node revenueJNJ 13,6%LLY 9,4%MRK 9,3%PFE 9,0%ABBV 8,8%AZN 8,4%BMY 6,9%GSK 6,2%Other 28,3%
    Source: company disclosures · own-taxonomy revenue-covered set · attribution: collision-suspect (indicative)PHAR 0,1% · rank #31 of 68

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs PHAR · multiples and returns
    JN
    JNJ
    Johnson & Johnson
    $254,43
    622,1B USD
    P/E
    23,5x
    vs self
    Div yield
    2,0 %
    vs self
    ROE
    33,0 %
    vs self
    LL
    LLY
    ELI LILLY AND COMPANY
    $1 124,04
    1,01T USD
    P/E
    52,0x
    vs self
    Div yield
    0,5 %
    vs self
    ROE
    66,2 %
    vs self
    MR
    MRK
    MERCK & CO., INC.
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    PF
    PFE
    Pfizer Inc
    $25,05
    143,6B USD
    P/E
    18,2x
    vs self
    Div yield
    6,9 %
    vs self
    ROE
    8,6 %
    vs self
    AB
    ABBV
    Abbvie Inc
    $245,10
    434,8B USD
    P/E
    110,6x
    vs self
    Div yield
    2,5 %
    vs self
    ROE
    -63,5 %
    vs self
    AZ
    AZN
    AZN.L
    $157,59
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    BM
    BMY
    Bristol-myers Squibb Co
    $65,60
    134,3B USD
    P/E
    17,7x
    vs self
    Div yield
    4,1 %
    vs self
    ROE
    31,6 %
    vs self
    GS
    GSK
    Gsk Plc-spon Adr
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,03
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    6
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-23 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$1,80
    Mean$2,21
    Median$2,23
    High$2,60
    Spot$158,25
    −98.6 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin391,1 %Best in class
    Net Margin517,2 %Best in class
    ROE9,6 %Above median
    Capex / Rev-2,5 %Above median
    D/E0,11Above median
    Cash Conv-0,21Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Colombo City Holdings PLC Market data — financials · 2026-05-28

    Ownership & reference

    Top holders

    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    — missing data

    Short positioning

    9.9Kshares short+210.4% vs prior
    1.45days to cover
    34.0%short of daily vol
    18fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    PHAR.CMCanonical
    — · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-07-30 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
    2026-07-30EVENTQ2 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-04FILING6-K filing →
    2026-05-28FILING6-K filing →
    2026-05-22FILING6-K filing →
    2026-05-07FILING6-K filing →
    2026-05-07FILING6-K filing →
    2026-04-16FILING6-K filing →
    2026-04-02FILING6-K filing →
    2026-04-02FILING20-F filing →
    2026-03-27FILING6-K filing →
    2026-03-24FILING6-K filing →
    2026-03-12FILING6-K filing →
    2026-02-03FILING6-K filing →
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage